Navigation Links
The “Plastic and Reconstructive Surgery Journal” Publishes Dr. John B. Tebbetts’ Study on Mastopexy and Breast Reduction
Date:7/25/2013

Dallas, TX (PRWEB) July 25, 2013

Dr. John B. Tebbetts, world renowned innovator in the field of breast augmentation, was recently published in the American Society of Plastic Surgeons’ "Plastic and Reconstructive Surgery Journal". The medical journal published a recent study by Dr. Tebbetts which was aimed at quantifying optimal nipple position and vertical and horizontal skin excess for mastopexy and breast reduction.

Dr. Tebbetts has been published in the "Plastic and Reconstructive Surgery Journal" previously for work relating to breast augmentation. His previous publishings recorded the successes of his 24 Hour Recovery® and High Five Measurement® System, as well as dual plane implant placement among other topics.

Dr. Tebbetts revolutionized the method in which breast augmentation is performed. He is the only surgeon to have recorded a zero percent reoperation rate in consecutive series of breast augmentation patients followed for at least three years in an FDA PMA study.

Dr. Tebbetts’ most recently published study followed 124 mastopexy and 122 breast reduction cases with an average follow-up of 4.6 years. Of the 246 patients, only 16 required reoperation, showing a reoperation rate of 6.5 percent. When compared to a study by the American Society of Plastic Surgeons which reported an average reoperation rate of 10-13 percent for breast lift patients, Dr. Tebbetts shows positive outcomes.

A common problem among women is the confusion over whether breast augmentation or breast lift is the correct course of action. Dr. Tebbetts’ High Five Measurement® System has resolved this problem. Dr. Tebbetts has researched and developed this method to be based on numbers, which eliminates all the guess work and uses the patient’s body to determine the solution.

Dr. Tebbetts’ work in the field of breast surgery, most recently mastopexy and breast lift, can help define the first steps of a comprehensive process for using objectively defined parameters that surgeons can apply to skin envelope design.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10952170.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. The Beverly Hills Facelift™ Elevates Facial Rejuvenation Using Natural Substances from the Body, Explains Facial Plastic and Reconstructive Surgeon Paul Nassif, M.D.
2. Study looks at sports-related facial fractures in kids, reports Plastic and Reconstructive Surgery
3. Jacque P. LeBeau, MD, Opening of the LeBeau Clinic, the Exclusive Center Specializing in Plastic and Reconstructive Surgery in Pensacola, Destin and Northern Gulf Coast
4. Dr. Benjamin Stong is the First Facial Plastic and Reconstructive Surgeon to Display the ABFPRS Board Certification Diplomate Logo
5. Gynecomastia has psychological impact on adolescent boys, reports plastic and reconstructive surgery
6. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Society for Peripheral Nerve & American Society for Reconstructive Microsurgery 2013 Meetings
7. AxoGen, Inc. to sponsor Educational Symposium and Panel Discussion at 2013 Annual Meetings of American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery
8. Plastic and Reconstructive Surgery Journal announces global expansion initiatives
9. The Society for Advanced Spinal Intervention Comments on Landmark Case, Calls for Standards in Minimally Invasive Spine Surgery
10. Florida Man Says Stryker’s Rejuvenate Hip Implant is Defective, Causing him Serious Injuries, Need for Revision Surgery, Alleges Lawsuit Filed by Parker Waichman LLP
11. DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Canadian Report That Shows Some Metal-on-Metal Hip Recipients More Likely to Need Revision Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: